4-(3-氯苯氧基)-苯甲酸 | 84403-70-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(3-氯苯氧基)-苯甲酸
• 中文别名: 4-(间氯苯氧)苯甲酸
• 英文名称: 4-(3-chlorobenzyloxy)benzoic acid
• 英文别名: 4-((3-Chlorobenzyl)oxy)benzoic acid；4-[(3-chlorophenyl)methoxy]benzoic acid
• CAS: 84403-70-3
• 化学式: C₁₄H₁₁ClO₃
• mdl: MFCD04114337
• 分子量: 262.693
• InChiKey: QMXPJNHJNFUZAT-UHFFFAOYSA-N

物化性质

• 沸点：
  423.4±25.0 °C(Predicted)
• 密度：
  1.322±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 海关编码：
  2918990090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  室温

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 4-[(3-Chlorobenzyl)Oxy]Benzoic Acid
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 4), H302
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Xn Harmful R22
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
Precautionary statement(s) none
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 262,7 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
4-[(3-Chlorobenzyl)Oxy]Benzoic Acid
Acute Tox. 4; H302 <= 100 %
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
4-[(3-Chlorobenzyl)Oxy]Benzoic Acid
Xn, R22 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non Combustible Solids
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and
at the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested
and approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges.
Use respirators and components tested and approved under appropriate government standards
such as NIOSH (US) or CEN (EU).
Control of environmental exposure
Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
No data available
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
For this product a chemical safety assessment was not carried out

---

SECTION 16: Other information
Full text of H-Statements referred to under sections 2 and 3.
Acute Tox. Acute toxicity
H302 Harmful if swallowed.
Full text of R-phrases referred to under sections 2 and 3
Xn Harmful
R22 Harmful if swallowed.
Further information
Copyright 2014 Co. LLC. License granted to make unlimited paper copies for internal use
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any
guarantee of the properties of the product. Corporation and its Affiliates shall not be held
liable for any damage resulting from handling or from contact with the above product. See
and/or the reverse side of invoice or packing slip for additional terms and conditions of sale.

反应信息

• 作为反应物：
  描述：

  4-(3-氯苯氧基)-苯甲酸 在 吡啶 、 氯化亚砜 作用下， 以 甲苯 、 乙腈 为溶剂， 反应 21.0h， 生成 N-(3-(1H-benzo[d]imidazol-2-yl)-4-methylphenylcarbamothioyl)-4-(3-chlorobenzyloxy)benzamide
  参考文献：
  名称：

  新型N -3-苯并咪唑苯基双酰胺衍生物的合成及其抗增殖和Hedgehog途径抑制活性的评估†

  摘要：

  合成了一系列带有4-苄氧基苯基部分的新颖的N -3-苯并咪唑苯基双酰胺衍生物，并评估了它们对MGC803，HT29，MKN45和SW620癌细胞系的体外抗增殖活性。药理数据表明，大多数目标化合物对MGC803，HT29和MKN45细胞具有更高的功效，其中化合物7m比vismodegib具有更高的抗增殖活性。此外，化合物7m在不同的Hh相关测定中显示出对Hedgehog（Hh）信号通路的抑制作用更好，并且可能与硼联吡啶（BODIPY）-环巴胺竞争与人类平滑（Smo）受体的结合。此外，分子对接研究表明，化合物7m通过Smo受体的taladegib结合位点上的氢键与vismodegib对接姿势非常紧密地相互作用。

  DOI：

  10.1039/c5md00092k
• 作为产物：
  描述：

  methyl 4-(3'-chlorobenzyloxy)-benzoate 在 水 、 sodium hydroxide 、 盐酸 作用下， 以 甲醇 、 水 为溶剂， 反应 2.0h， 以78%的产率得到4-(3-氯苯氧基)-苯甲酸
  参考文献：
  名称：

  新型N -3-苯并咪唑苯基双酰胺衍生物的合成及其抗增殖和Hedgehog途径抑制活性的评估†

  摘要：

  合成了一系列带有4-苄氧基苯基部分的新颖的N -3-苯并咪唑苯基双酰胺衍生物，并评估了它们对MGC803，HT29，MKN45和SW620癌细胞系的体外抗增殖活性。药理数据表明，大多数目标化合物对MGC803，HT29和MKN45细胞具有更高的功效，其中化合物7m比vismodegib具有更高的抗增殖活性。此外，化合物7m在不同的Hh相关测定中显示出对Hedgehog（Hh）信号通路的抑制作用更好，并且可能与硼联吡啶（BODIPY）-环巴胺竞争与人类平滑（Smo）受体的结合。此外，分子对接研究表明，化合物7m通过Smo受体的taladegib结合位点上的氢键与vismodegib对接姿势非常紧密地相互作用。

  DOI：

  10.1039/c5md00092k

文献信息

• 具潜在多靶点抗AD活性的甲酰胺吡啶酮类铁螯合剂衍生物及其制备方法与应用
  申请人：浙江工业大学

  公开号：CN111995567B

  公开（公告）日：2022-11-25

  本发明提供了一种式(I)或式(II)所示的甲酰胺吡啶酮类铁螯合剂衍生物及其制备方法与应用；所述式(I)或式(II)所示的甲酰胺吡啶酮类铁螯合剂衍生物及其药学上可接受的盐具有抑制单胺氧化酶、螯合金属铁离子、抗Aβ及抗氧化活性，可用于制备抗阿尔兹海默症、抗帕金森病或通过抑制单胺氧化酶、螯合金属铁离子、抗Aβ及抗氧化来治疗的其它病症的药物；
• Discovery of benzamide-hydroxypyridinone hybrids as potent multi-targeting agents for the treatment of Alzheimer's disease
  作者：Xiaoying Jiang、Jianan Guo、Changjun Zhang、Jinping Gu、Tao Zhou、Renren Bai、Yuanyuan Xie

  DOI：10.1080/14756366.2021.1978081

  日期：2021.1.1

  of Alzheimer's disease (AD) through pharmacophores-merged approaches based on lead compounds 18d, benzyloxy phenyl analogs, and deferiprone (DFP). These hybrids possessed potent Monoamine oxidase B (MAO-B) inhibition as well as excellent iron chelation, with pFe3+ values ranging from 18.13 to 19.39. Among all the compounds, 8g exhibited the most potent selective MAO-B inhibitor (IC50 = 68.4 nM, SI

  摘要 通过基于先导化合物18d、苄氧基苯基类似物和去铁酮的药效团合并方法，创新地设计、合成和生物学评估了一类新的苯甲酰胺-羟基吡啶酮 (HPO) 衍生物作为治疗阿尔茨海默病 (AD) 的潜在多靶点候选药物(DFP)。这些杂种具有有效的单胺氧化酶 B (MAO-B) 抑制作用以及出色的铁螯合性，pFe 3+值范围为 18.13 至 19.39。在所有化合物中，8g表现出最有效的选择性 MAO-B 抑制剂（IC 50 = 68.4 nM，SI = 213）。此外，8g显示出良好的药代动力学特性，并具有巨大的穿透 BBB 的潜力计算机和 PAMPA-BBB 测定。分子模型表明，8g可以采用扩展构象，并且与 MAO-B 的相互作用比18d更强。体外和体内试验表明，8g显着抵抗 Aβ 诱导的氧化并改善东莨菪碱诱导的认知障碍。综上所述，这些结果表明化合物8g是一种潜在的多功能抗 AD 治疗候选药物。
• Synthesis and Preliminary Biological Characterization of New Semisynthetic Derivatives of Ramoplanin
  作者：Romeo Ciabatti、Sonia I. Maffioli、Gianbattista Panzone、Augusto Canavesi、Elena Michelucci、Paolo S. Tiseni、Ettore Marzorati、Anna Checchia、Matteo Giannone、Daniela Jabes、Gabriella Romanò、Cristina Brunati、Gianpaolo Candiani、Franca Castiglione

  DOI：10.1021/jm070042z

  日期：2007.6.1

  of the new ramoplanin derivatives showed antimicrobial activity similar to that of the natural precursor coupled with a significantly improved local tolerability. Among them the derivative in which the 2-methylphenylacetic acid has replaced the di-unsaturated fatty acid side chain (48) was selected as the most interesting compound and submitted to further in vitro and in vivo characterization studies

  雷莫拉宁是一种糖脂肽肽抗生素，对革兰氏阳性细菌（包括耐万古霉素的肠球菌）具有活性。雷莫拉宁通过不同于糖肽的机制抑制细菌细胞壁的生物合成，因此对这些抗生素没有交叉耐药性。到目前为止，由于静脉内注射时局部耐受性低，因此一直无法阻止雷莫拉汀的全身使用。为了克服这个问题，选择性去除了拉莫普林的脂肪酸侧链，并用各种不同的羧酸代替。许多新的雷莫拉宁衍生物显示出与天然前体相似的抗微生物活性，并具有明显改善的局部耐受性。
• Design and biological evaluation of phenyl imidazole analogs as hedgehog signaling pathway inhibitors
  作者：Chiyu Sun、Ying Zhang、Han Wang、Zhengxu Yin、Lingqiong Wu、Yanmiao Huang、Wenhu Zhang、Youbing Wang、Qibo Hu

  DOI：10.1111/cbdd.13799

  日期：2021.3

  The hedgehog (Hh) signaling pathway is involved in diverse aspects of cellular events. Aberrant activation of Hh signaling pathway drives oncogenic transformation for a wide range of cancers, and it is therefore a promising target in cancer therapy. In the principle of association and ring‐opening, we designed and synthesized a series of Hh signaling pathway inhibitors with phenyl imidazole scaffold

  刺猬 (Hh) 信号通路参与细胞事件的各个方面。Hh 信号通路的异常激活驱动了多种癌症的致癌转化，因此它是癌症治疗的一个有希望的目标。本着缔合和开环原理，我们设计合成了一系列具有苯基咪唑支架的Hh信号通路抑制剂，并在Gli-Luc报告基因检测中进行了生物学评估。化合物25被鉴定为具有纳摩尔 IC 50 的高效能，此外，它保留了对野生型和耐药性 Smo 过表达细胞的抑制作用。化合物25的分子模型研究 阐述了其与Smo受体的结合方式，为苯基咪唑类似物的进一步结构修饰提供了基础。
• SMALL MOLECULE HEMATOPOIETIC GROWTH FACTOR MIMETIC COMPOUNDS THAT ACTIVATE HEMATOPOIETIC GROWTH FACTOR RECEPTORS
  申请人：Zhi Lin

  公开号：US20110003851A1

  公开（公告）日：2011-01-06

  The present embodiments relate to compounds with physiological effects, such as the activation of hematopoietic growth factor receptors. The present embodiments also relate to use of the compounds to treat a variety of conditions, diseases and ailments such as hematopoietic conditions and disorders.

  本实施例涉及具有生理作用的化合物，例如激活造血生长因子受体。本实施例还涉及使用这些化合物来治疗各种情况、疾病和疾患，例如造血系统的疾病和疾患。